The study is testing a treatment called CAP-1002 for Duchenne Muscular Dystrophy (DMD), a disease that weakens muscles over time. This trial will include boys and young men who can and cannot walk. The study is designed to see if CAP-1002 can help improve muscle function. Participants will receive either the treatment or a placebo, a fake treatment, every 3 months for 12 months. After that, everyone can receive the real treatment for another year.
Key Points:
- The study lasts for 24 months, with visits every 3 months.
- Participants will receive up to 8 treatments through an IV (a needle that goes into a vein).
- Safety and muscle function will be checked regularly with tests and exams.
The study is looking for boys and young men with DMD who are 10 years or older and meet specific health criteria. The treatment aims to improve upper limb function, heart health, and quality of life. Participation involves regular visits and monitoring. Potential risks include side effects from the treatment. Participants are required to follow specific health conditions and guidelines to be eligible.